| Analysis | Metabolite Name | Measured Value | Units | Group |
|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.2713 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.2713 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.2713 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.4827 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.5562 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.5621 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.5643 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.5730 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.5804 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.5841 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.5931 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6119 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6325 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6432 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6475 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6524 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6678 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6762 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6816 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.6842 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7096 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7158 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7250 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7326 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7332 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7441 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7443 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7639 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7681 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7867 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.7867 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8083 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8296 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8319 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8362 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8526 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8534 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8655 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8821 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8836 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.8972 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9245 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9314 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9434 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9508 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9581 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9676 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9684 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9778 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9886 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 0.9938 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0000 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0058 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0136 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0324 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0351 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0357 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0478 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0512 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0534 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.0895 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.1060 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.1137 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.1319 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.1468 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.1568 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.1666 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.1759 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.2035 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.2332 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.2691 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.2803 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.3036 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.3664 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.3822 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.4065 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.4362 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.4900 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.5174 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.5380 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.5582 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.6139 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.6886 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.7527 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.8115 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.9306 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.9523 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 1.9995 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 2.0661 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 2.4612 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 2.5460 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 2.5804 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 2.6669 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 2.9191 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 2.9769 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 3.3080 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 4.0488 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 4.0655 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 5.4414 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 5.4450 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | 4-hydroxyphenylacetate | 5.5699 | Peak area | Obese non neuropathy |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|